Cardiotoxicity of molecularly targeted agents

Current Cardiology Reviews

Volumn 7, Issue 4, 2011, Pages 221-233

  Hedhli, Nadia ^a   Russell, Kerry S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac toxicity; Cardiomyopathy; Chemotherapy; Proteasome inhibitors; Tyrosine kinases

Indexed keywords

AFLIBERCEPT; ALITRETINOIN; ANASTROZOLE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BEXAROTENE; BORTEZOMIB; CETUXIMAB; DASATINIB; ERLOTINIB; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; IMATINIB; LAPATINIB; LETROZOLE; NILOTINIB; PANITUMUMAB; PAZOPANIB; RETINOIC ACID; ROMIDEPSIN; SORAFENIB; SUNITINIB; TAMOXIFEN; TAMOXIFEN CITRATE; TEMSIROLIMUS; TOREMIFENE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; ZALTRAP;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ADVANCED CANCER; ANGINA PECTORIS; ANGIOGENESIS; BLEEDING; BRADYCARDIA; BRAIN HEMORRHAGE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOPULMONARY ARREST; CARDIOTOXICITY; CELL DEATH; CELL FUNCTION; CELL METABOLISM; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COLORECTAL CARCINOMA; CONGESTIVE HEART FAILURE; CUTANEOUS T CELL LYMPHOMA; DRUG MECHANISM; DRUG TARGETING; EDEMA; EMBOLIC PROTECTION DEVICE; EMBOLISM; FIBROSARCOMA; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MURMUR; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE EXTRASYSTOLE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPEREOSINOPHILIC SYNDROME; HYPERGLYCEMIA; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOGLYCEMIA; HYPOTENSION; HYPOTHYROIDISM; JAW PAIN; KAPOSI SARCOMA; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG EDEMA; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; META ANALYSIS (TOPIC); METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PERICARDIAL EFFUSION; PERICARDITIS; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; QT PROLONGATION; RAYNAUD PHENOMENON; REVIEW; SIDE EFFECT; SKIN LYMPHOMA; STOMACH CANCER; STROKE; SYNCOPE; SYSTEMIC MASTOCYTOSIS; T CELL LYMPHOMA; TACHYCARDIA; THORAX PAIN; THROMBOEMBOLISM; THROMBOPHLEBITIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYMUS CANCER; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CARDIOTOXINS; CARDIOVASCULAR DISEASES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84861315169     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/157340311799960636     Document Type: Review

References (147)

1. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23(13):2900-2.
2. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab- related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25(23):3525-33.
3. Hunter T, Cooper JA. Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells. Cell. 1981;24:741-52.
4. Schreiber AB, Lax I, Yarden Y, Eshhar Z, Schlessinger J. Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor. Proc Natl Acad Sci U S A. 1981;78(12):7535-9.
5. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A. 1983;80(5):1337-41.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-82.
7. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999;26(4 Suppl 12):78-83.
8. Ewer MS, Gibbs HR, Swafford J, Benjamin RS. Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol. 1999;26(4 Suppl 12):96-101.
9. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem. 1998;273:10261-9.
10. Russell KS, Stern DF, Polverini PJ, Bender JR. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol. 1999;277(6 Pt 2):H2205-11.
11. Lee K, Simon H, Chen H, Bates B, Hung M, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378:394-8.
12. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002;99(13):8880-5.
13. Hedhli N, Huang Q, Kalinowski A, Palmeri M, Hu X, Russell RR, et al. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation. 2011;123(20):2254-62.
14. Baliga RR, Pimental DR, Zhao YY, Simmons WW, Marchionni MA, Sawyer DB, et al. NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK- RSK. Am J Physiol. 1999;277(5 Pt 2):H2026-37.
15. Pentassuglia L, Sawyer DB. The role of Neuregulin-1beta/ErbB signaling in the heart. Exp Cell Res. 2009;315(4):627-37.
16. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820-6.
17. Hedhli N, Russell KS. Cytostatic drugs, neuregulin activation of erbB receptors, and angiogenesis. Curr Hypertens Rep. 2010;12(6):411-7.
18. Bagheri-Yarmand R, Vadlamudi RK, Wang RA, Mendelsohn J, Kumar R. Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1- mediated angiogenesis. J Biol Chem. 2000;275(50):39451-7.
19. Brutsaert DL, Meulemans AL, Sipido KR, Sys SU. Effects of damaging the endocardial surface on the mechanical performance of isolated cardiac muscle. Circ Res. 1988;62(2):358-66.
20. Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW. The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure. Curr Vasc Pharmacol. 2008;6(4):292-300.
21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-72.
22. Tan-Chiu E, Yothers G, Romond E, Geyer CE, Jr., Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2- overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811-9.
23. Herceptin Prescribing Information. Genentech, Inc. 2010:October 29, 2010.
24. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215-21.
25. Ewer MS, Tan-Chiu E. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well? J Clin Oncol. 2007;25(34):5532-3; author reply 3-4.
26. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910-6.
27. Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, et al. Management of cardiac health in trastuzumab- treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer. 2009;100(5):684-92.
28. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258-62.
29. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474-81.
30. Perez EA. Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin Breast Cancer. 2008;8 Suppl 3:S114-20.
31. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83(6):679-86.
32. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-6.
33. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993;143(5):1255-62.
34. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993;12(3-4):303-24.
35. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-42.
36. Konno H, Yamamoto M, Ohta M. Recent concepts of antiangiogenic therapy. Surg Today. 2010;40(6):494-500.
37. Cai J, Han S, Qing R, Liao D, Law B, Boulton ME. In pursuit of new anti-angiogenic therapies for cancer treatment. Front Biosci. 2011;16:803-14.
38. Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol. 2010;30(6):591-601.
39. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens. 2010;23(5):460-8.
40. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427-34.
41. Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009;15(19):6250-7.
42. Mir O, Mouthon L, Alexandre J, Mallion JM, Deray G, Guillevin L, et al. Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst. 2007;99(1):85-6.
43. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis. 2004;7(3):193-201.
44. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006;24(9):1363-9.
45. Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst. 2008;100(4):282-4.
46. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20(2):227-30.
47. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Jama. 2003;289(19):2560-72.
48. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(2):117-23.
49. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48(1):9-17.
50. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56(4):675-81.
51. Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol. 2002;22(9):1500-5.
52. Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol. 2009;22(1):115-28.
53. Kuenen BC. Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors. Pathophysiol Haemost Thromb. 2003;33 Suppl 1:13-4.
54. Schutz FA, Je Y, Choueiri TK. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: A meta- analysis of clinical trials. Crit Rev Oncol Hematol. 2010.
55. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, et al. Clinical outcomes associated with bevacizumab- containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14(9):862-70.
56. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20(11):1842-7.
57. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. Jama. 2008;300(19):2277-85.
58. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28(13):2280-5.
59. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol. 2009;10(10):967-74.
60. Minor DR. Risk of arterial thrombosis not increased by sorafenib or sunitinib. J Clin Oncol. 2010;28(30):e619; author reply e20.
61. Minor DR. Risk of bleeding not increased by sorafenib or sunitinib. Lancet Oncol. 2010;11(2):112-3; author reply 3.
62. Hapani S, Sher A, Chu D, Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. oncology. 2010;79(1-2):27-38.
63. Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res. 2009;15(22):7045-52.
64. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231-47.
65. Bagnes C, Panchuk PN, Recondo G. Antineoplastic chemotherapy induced QTc prolongation. Curr Drug Saf. 2010;5(1):93-6.
66. Heba G, Krzeminski T, Porc M, Grzyb J, Ratajska A, Dembinska-Kiec A. The time course of tumor necrosis factor-alpha, inducible nitric oxide synthase and vascular endothelial growth factor expression in an experimental model of chronic myocardial infarction in rats. J Vasc Res. 2001;38(3):288-300.
67. Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia- inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci. 2005;12(2):409-20.
68. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension. 2006;47(5):887-93.
69. Yardley DA. Integrating bevacizumab into the treatment of patients with early-stage breast cancer: focus on cardiac safety. Clin Breast Cancer. 2010;10(2):119-29.
70. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti- vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist. 2010;15(2):130-41.
71. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011-9.
72. Di Lorenzo G, Autorino R, Bruni G, Carteni G, Ricevuto E, Tudini M, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009;20(9):1535-42.
73. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112(11):2500-8.
74. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008;19(9):1613-8.
75. Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 2008;106(1):153-61.
76. Chintalgattu V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TL, et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest. 2010;120(2):472-84.
77. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054-61.
78. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908-16.
79. Tiribelli M, Medeot M. Cardiotoxicity of imatinib: At the heart of the problem. Leuk Res. 2011;35(1):36-7.
80. Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, et al. Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res. 2010;34(9):1180-8.
81. Tiribelli M, Colatutto A, Marin L, Barbina G, Qualizza U, Damiani D, et al. Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. Am J Hematol. 2008;83(6):517-8.
82. Estabragh ZR, Knight K, Watmough SJ, Lane S, Vinjamuri S, Hart G, et al. A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. Leuk Res. 2011;35(1):49-51.
83. Marcolino MS, Ribeiro AL, Clementino NC, Nunes Mdo C, Barbosa MM, Silva MH, et al. The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia. Leuk Res. 2011;35(3):317-22.
84. Hatfield A, Owen S, Pilot PR. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med. 2007;13(1):13; author reply 5-6.
85. Breccia M. Is imatinib-related cardiotoxicity still an open issue? Leuk Res. 2011;35(1):34-5.
86. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009;48(7):964-70.
87. Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol. 2009;4(2):99-105.
88. Breccia M, Alimena G. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development. Expert Opin Drug Saf. 2010;9(5):713-21.
89. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9-22.
90. Malizzia LJ, Hsu A. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clin J Oncol Nurs. 2008;12(4):639-46.
91. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4(5):335-48.
92. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530-40.
93. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol. 2008;19(8):1387-92.
94. Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer. 2006;42(12):1875-80.
95. Dancey JE, Curiel R, Purvis J. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin Oncol. 2009;36 Suppl 3:S46-58.
96. Wong B. Medical therapy in Urology 2010. 2010. p. 13-7.
97. Valantine H, Zuckermann A. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation. J Heart Lung Transplant. 2005;24(4 Suppl):S185-90; discussion S210-1.
98. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-56.
99. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9(4):777-94.
100. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. Jama. 2002;288(7):872-81.
101. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18(11):937-47.
102. Harvey HA, Kimura M, Hajba A. Toremifene: an evaluation of its safety profile. Breast. 2006;15(2):142-57.
103. Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst. 2010;102(13):942-9.
104. Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long- term safety analysis of the ATAC trial. Lancet Oncol. 2006;7(8):633-43.
105. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early- stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45-53.
106. Lenihan DJ, Esteva FJ. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist. 2008;13(12):1224-34.
107. Smith MR, Malkowicz SB, Chu F, Forrest J, Sieber P, Barnette KG, et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol. 2008;26(11):1824-9.
108. Tominaga T, Kimijima I, Kimura M, Takatsuka Y, Takashima S, Nomura Y, et al. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. Jpn J Clin Oncol. 2010;40(7):627-33.
109. Ponzone R, Mininanni P, Cassina E, Pastorino F, Sismondi P. Aromatase inhibitors for breast cancer: different structures, same effects? Endocr Relat Cancer. 2008;15(1):27-36.
110. Gandhi S, Verma S. Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter. Breast Cancer Res Treat. 2007;106(1):1-9.
111. Cuppone F, Bria E, Verma S, Pritchard KI, Gandhi S, Carlini P, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta- analysis of randomized trials. Cancer. 2008;112(2):260-7.
112. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25(5):486-92.
113. Mouridsen H, Keshaviah A, Coates AS, Rabaglio M, Castiglione-Gertsch M, Sun Z, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007;25(36):5715-22.
114. Amir E, Ocaña A, Niraula S, Carlsson L, Seruga B. Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients. San Antonio Breast Cancer Symposium. 2010:S2-7.
115. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1(3):194-202.
116. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92(15):1210-6.
117. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A. 2005;102(44):16090-5.
118. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell. 2002;111(5):709-20.
119. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 2002;21(3):427-36.
120. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27(32):5459-68.
121. Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 2009;280(2):192-200.
122. Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2006;12(13):3997-4003.
123. Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006;5(1):57-60.
124. Mongan NP, Gudas LJ. Diverse actions of retinoid receptors in cancer prevention and treatment. Differentiation. 2007;75(9):853-70.
125. Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol. 2011;6:345-64.
126. Simbre IV, Adams MJ, Deshpande SS, Duffy SA, Miller TL, Lipshultz SE. Cardiomyopathy Caused by Antineoplastic Therapies. Curr Treat Options Cardiovasc Med. 2001;3(6):493-505.
127. Gore SD, Gojo I, Sekeres MA, Morris L, Devetten M, Jamieson K, et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol. 2010;28(6):1047-53.
128. Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer. 2005;104(12):2717-25.
129. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther. 2006;6(9):1249-69.
130. Latagliata R, Avvisati G, Lo Coco F, Petti MC, Diverio D, Spadea A, et al. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years. Ann Oncol. 1997;8(12):1273-5.
131. Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer. 2006;6:129.
132. Jerkins J, Suciua A, Mazimbaa S, Calvo A. Bortezomib-induced Severe Congestive Heart Failure. Cardiol Res. 2010;1(1):20-3.
133. Hedhli N, Lizano P, Hong C, Fritzky LF, Dhar SK, Liu H, et al. Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload. Am J Physiol Heart Circ Physiol. 2008;295(4):H1385-93.
134. Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 2005;104(10):2141-8.
135. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487-98.
136. Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side- effects of cancer chemotherapy. Int J Cardiol. 2010;144(1):3-15.
137. Chaudhary P, Gajra A. Cardiovascular effects of EGFR (epidermal growth factor receptor) monoclonal antibodies. Cardiovasc Hematol Agents Med Chem. 2010;8(3):156-63.
138. Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, et al. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2010;5(7):1054-9.
139. Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol. 2010;11(5):465-75.
140. Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist. 2010;15(7):683-94.
141. Corporation NP. AFINITOR - everolimus tablet Drug Label. http://dailymednlmnihgov/dailymed/archives/fdaDrugInfocfm?archiveid=143552009.
142. Reis SE, Costantino JP, Wickerham DL, Tan-Chiu E, Wang J, Kavanah M. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst. 2001;93(1):16-21.
143. Bradbury BD, Lash TL, Kaye JA, Jick SS. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer. 2005;103(6):1114-21.
144. Pyrhonen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study. Br J Cancer. 1997;76(2):270-7.
145. Keating GM. Letrozole: a review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer. Drugs. 2009;69(12):1681-705.
146. Zhang L, Lebwohl D, Masson E, Laird G, Cooper MR, Prince HM. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat). J Clin Oncol. 2008;26(2):332-3; discussion 3-4.
147. De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1998;92(8):2712-8.